News

Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.

With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.

According to 3x3 mm and 6x6 mm OCTA scans, there were no significant changes in mean macular intercapillary area measures for all tested regions.

96.4% of patients in symptomatic remission at week 152 were corticosteroid-free.

Several different treatments appear to be efficacious in this patient population.

A variety of online drowning prevention resources can be accessed by parents and health care professionals, promoting safe swimming in the summer.

Researchers found the strongest associations between ADHD and nervous system disorders and respiratory diseases.

Data from COMPASS show adding low-dose low-dose rivaroxaban to aspirin resulted in benefits regardless of number of concomitant drugs or comorbidities.

FlowMetric, Inc., discusses its VaxEffect, an immune monitoring platform and how it can be used to measure COVID-19 vaccine responses.

The new PDUFA date for the biologic has been scheduled for early 2022.

There was no evidence found suggesting children with lower emotion regulation ability at years old had greater probability of later reporting symptoms of broad anorexia nervosa.

A maternal-infant HCV linkage program in combination with a multidisciplinary clinic to collocate mother and infant care was implemented in 2016.

Dr. Manesh Patel shares perspective on the "renaissance of anti-thrombotic therapy" for patients at risk of cardiovascular events.

The overall serum anti-toxin A and B antibody levels were similar at baseline between immunocompromised hosts and non-immunocompromised hosts.

Investigators show that both terms tend to be used in different contexts within the biomedical literature.

Physicians who performed well on ABIM examination less likely to prescribe opioids for back pain compared to physicians who did not perform well.

Schuyler Jones, MD discusses risk stratification in CAD/PAD and treatments aimed at atherothrombosis.

Post-survey responses show educators were eager to learn more about how to prevent students from experiencing food-anaphylactic reactions.

Florian Thomas, MD, and Adrian Hepner, MD, cover the basics of the degenerative nerve disorder.

Growing evidence shows promise of stroke prevention with anti-thrombotic therapy in patients with AF.

Research shows that detailed systems of care for infants suffering with BPD are integral in managing the national rate of infection.

Telemedicine could be useful if it is added to regimen of in-person health care visits.

The new PDUFA date for avacopan has been pushed back to October 7.

The EMPEROR-Preserved trial demonstrated safety and efficacy of empagliflozin for patients with heart failure across spectrum of ejection fraction.

FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.

The study highlights the myriad of physical and emotional complications in young patients in the London area.

Patients included in the high-dose group demonstrated statistically significant improvements compared to placebo for MDS-UPDRS total score.

Cases were identified by searching the Veterans Affairs Corporate Data Warehouse.